Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer

YORK, Pa., July 19, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced it has commenced the initial sale of the Unifill® ready-to-fill syringe to a U.S.-based global pharmaceutical company.

The commencement of Unifill sales to this new customer, whose identity remains confidential at this time, follows the initial shipment of the device to Sanofi last week.  Unilife continues to expand its customer pipeline as an increasing number of pharmaceutical companies seek access to Unifill for the delivery of their prefilled injectable drugs.

Unilife expects this new U.S.-based pharmaceutical customer to conduct drug compatibility and stability tests with their injectable drugs in combination with Unifill as per standard industry practices for drug-device combination products. The resulting data is then filed to regulatory agencies as a final step before approval. 

Mr. Alan Shortall, CEO of Unilife, said, "Unilife is pleased to have commenced initial sales of the Unifill syringe to another global pharmaceutical company.  We expect to continue supplying the Unifill syringe to this customer over the coming months to support their drug compatibility and stability tests with a number of target molecules.

"The Unifill syringe is the world's first and only known prefilled syringe with safety features fully integrated within the glass barrel. The Unifill syringe is essentially a primary drug container, a safety device and a sharps disposal unit all rolled into one. It is strongly positioned to help improve patient care and better protect healthcare workers at risk of contracting infectious diseases, such as HIV via needlestick injuries and other potential transmission modes.

"We are pleased with the strong level of interest in the Unifill syringe from a significant number of pharmaceutical and biotechnology companies that recognize its potential to optimize the lifecycles of their injectable drugs and generate powerful brand differentiation within competitive therapeutic classes. We look forward to entering into agreements with a number of additional pharmaceutical partners over the coming months."

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.  For more information on Unilife, please visit www.unilife.com. 

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.